Last reviewed · How we verify
Standard of Care Rescue Medication
Standard of Care Rescue Medication is a Small molecule drug developed by Teva Branded Pharmaceutical Products R&D, Inc.. It is currently FDA-approved.
Standard of Care Rescue Medication refers to an established, approved therapeutic agent used as a backup treatment when primary therapies fail or are contraindicated.
At a glance
| Generic name | Standard of Care Rescue Medication |
|---|---|
| Sponsor | Teva Branded Pharmaceutical Products R&D, Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
This is a categorical designation rather than a specific drug, encompassing various approved medications used in clinical practice as rescue or salvage therapy. The specific mechanism depends on the therapeutic context and the particular agent deployed, which varies by indication and clinical setting.
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (PHASE3)
- A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) (PHASE3)
- A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) (PHASE1, PHASE2)
- A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) (PHASE3)
- A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma (PHASE4)
- The Impact of a Shared Decision-Making Intervention on Intraoperative Patient Experience During Elective Cesarean Delivery Under Spinal Anesthesia (NA)
- Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) (PHASE1, PHASE2)
- The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard of Care Rescue Medication CI brief — competitive landscape report
- Standard of Care Rescue Medication updates RSS · CI watch RSS
- Teva Branded Pharmaceutical Products R&D, Inc. portfolio CI